We excluded variants with MAF > 0.5% in either the Exome Aggregation Consortium (ExAC) and/or the ICR1000 UK exome series. For the de novo analyses, we identified and validated any high-quality (as defined by OpEx18) variant in the child that was not present in either parent. We evaluated and validated all rare variants identified in the 14 genes.